TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04768478

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CBD
Description: 25mg CBD ODTs (orally disintegrating tablet), with instructions to take CBD tablets t.i.d. (total of 50mg per dose t.i.d.) to be administered with routine post-operative pain management
Study: NCT04190303

Intervention type: OTHER
Intervention: Pragmatic, multi-component package
Description: This system-level intervention will be tailored to the needs and capacity of each hospital site, co-developed with policymakers and hospital staff
Study: NCT03992469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EBFAHF-2
Description: EBFAHF-2 is a 0.55g capsule that is easy to swallow. The quality, safety and consistency of EBFAHF-2 are established per FDA guidance under a botanical drug title. Low dose (maximum of 2 capsules bid) and full dose (maximum of 5 capsules bid). Weight based dosing will ensure an equivalent amount is given to each individual.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules made of cornstarch
Study: NCT05400213

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vallos
Description: Demineralized freeze-dried bone allograft (DFBA) in a small particle form

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vallomix
Description: A combination of cow-derived xenograft and human-derived DFDBA particulate

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vallos-F
Description: Demineralized freeze-dried bone allograft (DFDBA) in a fiber form

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vallomix-F
Description: A combination of cow-derived xenograft and human-derived DFDBA fibers
Study: NCT06500533

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS combined with tDCS
Description: The intervention will last 30 days per patient, where rTMS will be administered on odd numbered days (study day 1, 3, 5, 7, ..29) and tDCS on even numbered days (study day 2, 4, 6, 8, ... 30). All patients will start with TMS and finish with home-based tDCS treatment. Both rTMS and tDCS treatments will be administered during working days, from Monday to Friday.~rTMS treatment will be administered by the experienced nurses of the rTMS clinic of each department. The rTMS treatment will profit from ongoing supervision by the Clinical Directors of each TMS clinic, which is in line with treatment as usual.~tDCS will be performed at home by the patients.
Study: NCT04851964

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental: Tezepelumab
Description: Tezepelumab subcutaneous injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneous injection
Study: NCT05091190

Intervention type: OTHER
Group type: OTHER
Intervention: Blood draws
Description: Blood draws will be realized at the following time points:~C1T1: at the baseline, before treatment administration. C1T2: cycle 1, after treatment administration. C2T1: the day of the 2nd cycle, before treatment administration. C2T2: the day of 2nd cycle, after treatment administration. C3T1: the day of the 3rd cycle, before treatment administration. C3T2: the day of 3rd cycle, after treatment administration.
Study: NCT05943626

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Circadian Intervention
Description: The circadian intervention group will receive counseling and instruction to reduce evening and nighttime light exposure, increase morning room light and sunlight exposure, and to finish all food consumption at least 4 hours before bedtime.
Study: NCT06295731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INBRX-106
Description: INBRX-106 by intravenous (IV) infusion, given every 3 weeks (QW3)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: INBRX-106
Description: INBRX-106 by intravenous (IV) infusion, given every 3 weeks (QW3)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg by intravenous (IV) infusion, given every 3 weeks (QW3)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg by intravenous (IV) infusion, given every 3 weeks (QW3)
Study: NCT04768478

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Visually indistinguishable placebo ODTs, with instructions to take two tablets t.i.d., to be administered with routine post-operative pain management
Study: NCT04005443

Intervention type: OTHER
Group type: OTHER
Intervention: radiopharmaceutical
Description: his study will consist of a monthly intra-ocular injection of antiangiogenic and a follow-up ophthalmological consultation with OCT and visual acuity score
Study: NCT05817773

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: breastfeeding cradle
Description: Mothers with postop mobile cesarean section should be breastfed with a nursing cradle for 30 minutes every 2-3 hours, even if the baby does not cry, until after mobilization (for 6 hours after coming to the service) every time the baby cries.
Study: NCT04869956

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary pattern : High-fiber diet rich in PUFA
Description: High-fiber diet rich in PUFAs (total dietary intake of at least 30 grams of fiber per day, and of at least 3 grams of PUFAs per day from food, not supplements) at least 4 weeks before surgery

Intervention type: OTHER
Group type: OTHER
Intervention: Dietary pattern: Standard diet
Description: standard nutritional recommendations
Study: NCT05431582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZN-c3
Description: Given by PO 1 time a day with a glass (about 8 ounces) of water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZN-c3
Description: Given by PO 1 time a day with a glass (about 8 ounces) of water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given by vein over about 30-60 minutes on Day 1 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given by vein over about 30-60 minutes on Day 1 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given by vein over 30-60 minutes on Day 1 of each cycle.
Study: NCT04667195

Intervention type: OTHER
Intervention: Clinical assessment
Description: Within 4 hours of admission to the emergency department, clinical assessment will include:~* Demographics,~* comorbidity,~* symptoms,~* objective findings,~* triage at admission,~* blood test results,~* urine test results
Study: NCT04930640

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SGF200 group
Description: 1 times a day, 1 capsule for 1 time, before breakfast meal, for 8 week

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 8 week
Study: NCT06348134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine
Description: A chemotherapy drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine
Description: A chemotherapy drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine
Description: A chemotherapy drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab Injection
Description: A prescription medicine that is approved for use in combination with trastuzumab and docetaxel in people who have HER2-positive breast cancer that has spread to different parts of the body (metastatic) and who have not received anti-HER2 therapy or chemotherapy for metastatic breast cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab Injection
Description: A prescription medicine that is approved for use in combination with trastuzumab and docetaxel in people who have HER2-positive breast cancer that has spread to different parts of the body (metastatic) and who have not received anti-HER2 therapy or chemotherapy for metastatic breast cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: A chemotherapy drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: A chemotherapy drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: A medication used to treat breast cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: A medication used to treat breast cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Description: A hormone therapy drug.
Study: NCT06418152

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-modal treatment
Description: Multi-modal treatment was designed to target PD-specific declines in the areas of cognitive function and gait and posture impairments. MMT consists of simultaneously training a motor and cognitive task.
Study: NCT05003882

Intervention type: OTHER
Intervention: Commercially available, orally ingestible CBD product
Description: botanically-derived CBD extract product
Study: NCT06361277

Intervention type: DRUG
Group type: OTHER
Intervention: Reference Drug or Test Drug
Description: Tablet, Oral, QD for 1 Day, Washout period is more than 7 days after administration

Intervention type: DRUG
Group type: OTHER
Intervention: Reference Drug or Test Drug
Description: Tablet, Oral, QD for 1 Day, Washout period is more than 7 days after administration
Study: NCT04650321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab at home
Description: Patients will receive ocrelizumab infusion at home.
Study: NCT05515549

Intervention type: OTHER
Intervention: Venous blood was collected from patients under fasting state to detect the level of thrombus molecular markers
Description: The venous blood of the patients in fasting state was collected to detect the level of thrombus molecular markers. Color Doppler ultrasound was used as the gold standard to determine whether VTE occurred. According to the color Doppler ultrasound diagnosis results, the patients were divided into VTE group and non VTE group.

Intervention type: OTHER
Intervention: Venous blood was collected from patients under fasting state to detect the level of thrombus molecular markers
Description: The venous blood of the patients in fasting state was collected to detect the level of thrombus molecular markers. Color Doppler ultrasound was used as the gold standard to determine whether VTE occurred. According to the color Doppler ultrasound diagnosis results, the patients were divided into VTE group and non VTE group.
Study: NCT05623605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moringa mouthwash
Description: using Moringa mouthwashes in 3 different concentrations (5,10,15%) twice per day for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: star anise mouthwash
Description: using star anise mouthwash in 3 different concentrations (5,10,15%) twice per day for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indian costus mouth wash
Description: using Indian costus mouthwash in 3 different concentrations (5,10,15%) twice per day for 7 days
Study: NCT05657743

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
Description: An intratumoral insertion of radioactive sources \[Ra-224 containing stainless-steel 316LVM tubes- (Alpha DaRT seeds)\]. The seeds release by recoil into the tumor short-lived alpha-emitting atoms
Study: NCT05251935

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foot Muscle Exercise Protocol
Description: Foot Muscle Exercise was given for 3 days per week for 40 minutes for the period of 6 months including home program

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Arch Support Insole and One Leg Balance Activities
Description: Arch Support Insoles were provided that the child had to wear for 5 hours per day thrice weekly for 6 months plus performed one leg balance activities
Study: NCT06289283

Intervention type: OTHER
Intervention: Urine samples and tissue samples: Samples will be collected in clean leak-proof containers without disinfectant or detergent residue and with tight-fitting leak-proof lids and preserved in a refrigera
Description: Samples for microbiome analysis:~Samples will be collected in clean leak-proof containers without disinfectant or detergent residue and with tight-fitting leak-proof lids and preserved in a refrigerator until be analyzed at the microbiology laboratory of TBRI.~Urine samples (50 ml) for microbiome analysis will be collected during cystoscopy examination. Samples will be stored at -80 °C until processing.~Tissue and urine samples from patients with bladder cancer: Under standard procedure of diagnostic cystoscopy urine sample will be collected under complete aseptic conditions, patients who has bladder tumor will undergo transurethral resection of bladder tumor, a tissue sample 0.5x0.5 cm will be investigated for microbiome analysis. Samples will be stored at -80 °C until processing. Histopathological diagnosis with Hematoxylin and eosin stain will be done by an expert pathologist for tumor grade and stage according to WHO 22, and EAU guidelines 2023. This procedure will be applied for
Study: NCT05187910

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Speech Therapy
Description: Training with a Speech Language Pathologists for voice disorders. This is typically done with an initial visit done jointly with an MD physician. Then there are 4 subsequent therapy visits in addition to home practice exercises. Finally there will be another joint post-treatment evaluation to determine progress and next steps.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Swallowing Therapy
Description: Training with a Speech Language Pathologists for swallowing disorders. This is typically done with an initial visit done jointly with an MD physician. Then there are 4 subsequent therapy visits in addition to home practice exercises. Finally there will be another joint post-treatment evaluation to determine progress and next steps.
Study: NCT05003882

Intervention type: OTHER
Intervention: Commercially available, orally ingestible CBD product
Description: botanically-derived CBD extract product

Intervention type: OTHER
Intervention: Commercially available, orally ingestible CBD product
Description: botanically-derived CBD extract product

Intervention type: OTHER
Intervention: Commercially available, orally ingestible CBD product
Description: botanically-derived CBD extract product

Intervention type: OTHER
Intervention: Commercially available, orally ingestible CBD product
Description: botanically-derived CBD extract product

Intervention type: OTHER
Intervention: Commercially available, orally ingestible CBD product
Description: botanically-derived CBD extract product

Intervention type: OTHER
Intervention: Commercially available, orally ingestible CBD product
Description: botanically-derived CBD extract product

Intervention type: OTHER
Intervention: Commercially available, orally ingestible CBD product
Description: botanically-derived CBD extract product

Intervention type: OTHER
Intervention: Commercially available, orally ingestible CBD product
Description: botanically-derived CBD extract product

Intervention type: OTHER
Intervention: Commercially available, orally ingestible CBD product
Description: botanically-derived CBD extract product
Study: NCT04919993

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy-Insomnia
Description: Group presentation
Study: NCT05568849

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: OCTA measurements
Description: OCTA images will be obtained from the retina at 1-3 time points around the time of children's heart surgery
Study: NCT05187910

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Upper Airway Therapy
Description: Training with a Speech Language Pathologists for upper airway disorders. This is typically done with an initial visit done jointly with an MD physician. Then there are 4 subsequent therapy visits in addition to home practice exercises. Finally there will be another joint post-treatment evaluation to determine progress and next steps.
Study: NCT06375915

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radioembolization with Y-90
Description: Radioembolization with Y-90 will be performed in nominal day 0
Study: NCT06490822

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Skin biopsy
Description: A single 3 mm-diameter punch skin biopsy will be obtained from FTLD patients and healthy volunteers at the C8 paravertebral under local anesthesia to analyze cutaneous innervation
Study: NCT06375915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Following radioembolization, for 6 cycles -intravenous infusion on day 1 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Following radioembolization, for 6 cycles -intravenous infusion on day 1 and 8 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Following radioembolization, for 6 cycles -intravenous infusion on day 1 and 8 of each cycle
Study: NCT05056519

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live Attenuated Influenza Vaccine
Description: Live Attenuated Influenza Vaccine placebo, containing H1, H3 and B type influenza Live Attenuated virus.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Live Attenuated Influenza Vaccine placebo
Description: Live Attenuated Influenza Vaccine placebo, not containing H1, H3 and B type influenza Live Attenuated virus.
Study: NCT04715906

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: UP-Caregiver
Description: The Unified Protocol (UP) is a telehealth group session using Zoom with each session lasting approximately 60-90 minutes. The sessions will focus on a variety of Cognitive Behavior Therapy techniques. These sessions may include teaching coping skills, goal setting, parent-child problem solving and communication, and motivation during this pandemic.
Study: NCT05984823

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home based body weight type exercises with blood flow restriction
Description: The participant will be asked to complete blood flow restricted exercises described below three times per week for 6 weeks.~Exercise protocol: Two tourniquets will be placed around the upper part of each thigh, these tourniquets will be inflated to an individualised and maintained for the duration of each exercise (including the inter-set rest period) but deflated during the 5 min rest in between. Five Body weight Exercises will be performed: Sitting knee extensions, standing knee raise, Heel-toe raises, Bilateral, mini-squat behind a chair, and Chair rise/sit to stand.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home based body weight type exercises
Description: The participant will be asked to complete body weight exercises for three times per week for 6 weeks. These exercises include: Sitting knee extensions, standing knee raise, Heel-toe raises, Bilateral, mini-squat behind a chair, and Chair rise/sit to stand.
Study: NCT06253117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: Pirfenidone Days 1-7: 267 mg PO TID (801 mg/day) Days 8-14: 534 mg PO TID (1602 mg/day) Day 15 and thereafter: 801 mg PO TID; not to exceed 2403 mg/day~Duration of treatment- total 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05907967

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VeNS
Description: The VeNS device utilizes a technology called galvanic vestibular stimulation (GVS) (sometimes termed vestibular nerve stimulation (VeNS)). The device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 30 minutes per day.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: VeNS
Description: The VeNS device utilizes a technology called galvanic vestibular stimulation (GVS) (sometimes termed vestibular nerve stimulation (VeNS)). The device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 30 minutes per day.
Study: NCT05030623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil 5Mg Tab
Description: Tadalafil 5Mg Tab plus Fluoxetine 20 mg capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Tab plus Fluoxetine 20 mg capsule
Study: NCT06212557

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KIOS App
Description: KIOS provides patients on demand individualized advice and reinforcement of lifestyle interventions to improve self-management during Medication-Assisted Treatment (MAT)

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: KIOS App education
Description: Educational tools provided to participants with opioid use disorder

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: Behavioral counseling in clinic

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Treatment as usual
Description: Behavioral counseling in clinic
Study: NCT06004531

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prompting open-ended question promoting sustainability
Description: This intervention will include active persuasion through prompting participants to answer an open-ended question regarding how they will alter their behavior to become more sustainable and eco-friendly.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prompting open-ended question promoting sustainability
Description: This intervention will include active persuasion through prompting participants to answer an open-ended question regarding how they will alter their behavior to become more sustainable and eco-friendly.
Study: NCT05336994

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multivitamin/mineral supplement A
Description: Oral administration of Supplement A

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multivitamin/mineral supplement A
Description: Oral administration of Supplement A
Study: NCT06004531

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sustainability Passage
Description: This intervention will include passive persuasion through presenting participants with a passage discussing the serious issue of climate change and the pressing need for systemic and individual change to adopt sustainable practices and lifestyles.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sustainability Passage
Description: This intervention will include passive persuasion through presenting participants with a passage discussing the serious issue of climate change and the pressing need for systemic and individual change to adopt sustainable practices and lifestyles.
Study: NCT05336994

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multivitamin/mineral supplement B
Description: Oral administration of Supplement B

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multivitamin/mineral supplement B
Description: Oral administration of Supplement B